Multivariate analysis for estimation of the chemopreventive effect of metformin in diabetic patients
| Diabetic patients (N=47 820) | ORs (95% CI) | p Value |
|---|---|---|
| Metformin use (user vs non-users) | 0.79 (0.75 to 0.83) | <0.0001 |
| Age (each incremental year) | 1.00 (1.00 to 1.00) | 0.3031 |
| Gender (male vs female) | 1.06 (1.01 to 1.11) | 0.0216 |
| Hepatitis B | 14.58 (13.28 to 16.02) | <0.0001 |
| Hepatitis C | 18.02 (16.40 to 19.79) | <0.0001 |
| Liver cirrhosis | 3.14 (2.62 to 3.75) | <0.0001 |
| End stage renal failure | 0.68 (0.63 to 0.73) | <0.0001 |
| DM duration (each incremental year) | 0.92 (0.91 to 0.93) | <0.0001 |
| DM control (each incremental visit per year) | 1.00 (1.00 to 1.01) | 0.6694 |
| Other OHA agents use (users vs non-users) | 1.20 (1.10 to 1.30) | <0.0001 |
| Thiazolidinediones use (users vs non-users) | 0.76 (0.70 to 0.81) | <0.0001 |
| Insulin use (users vs non-users) | 4.37 (4.17 to 4.59) | <0.0001 |
DM, diabetes mellitus; OHA, oral hypoglycaemic agent.